Nipro Diagnostics gets FDA approval for blood-glucose monitors

FORT LAUDERDALE, Fla. — Nipro Diagnostics announced that the Food and Drug Administration approved its True Metrix self-monitoring blood-glucose system, as well as the True Metrix Pro professional monitoring blood-glucose system. The company made the announcement at the National Association of Chain Drug Stores Total Store Expo in Boston.



The meters use pre- and post-meal tags that allow patients to mark results to help better understand how food affects blood glucose. Patients also are able to tie noteworthy events — exercise, medication, sickness and other occasions — to blood glucose readings to determine patterns and trends, helping them to make better decisions in the management of diabetes, the company said.



“It is essential as the store brand leader in diabetes that we continue to innovate from both a technology and a business perspective. The evolving payer landscape, driven by demands of increased clinical performance and economic accountability, has created a market energized in disruption. The True Metrix blood glucose monitoring platform reinforces our commitment to offer an innovative, affordable solution for diabetes patients to lead healthier lives,” Scott Verner, CEO and president of Nipro Diagnostics, said.



True Metrix will be available through retail, mail and distribution channels beginning fourth-quarter 2014.